WASHINGTON, Sept 4 (Reuters) - The U.S. State Department

announced a plan on Thursday to bring Gilead Sciences Inc's ( GILD )

drug lenacapavir to market "at cost" in high-burden HIV

countries in an effort to reach 2 million people over three

years.

The company will offer the long-acting HIV prevention drug

to the Global Fund and the U.S. government's PEPFAR program

without profit, government and company officials said at a news

briefing.